approximately 50 times more potent (yes, 50!) than d-methadone. The d-methadone isomer is completely devoid of opioid activity but acts on the NDMA receptors in the brain.
“We are extremely pleased to have completed this milestone as we continue to make progress with the development of our chronic pain relief solutions,” stated Sergio Traversa, CEO of Relmada Therapeutics. “There is a huge potential market for a treatment that can address neuropathic pain. If we can demonstrate that d-methadone has analgesic efficacy in this painful condition, we strongly believe that it has the potential to be a blockbuster drug in this large and unsatisfied market."